TipRanks
Advertisement
Advertisement

DE:1YI0 Stock Latest News

Purple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle
Company AnnouncementsPurple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle
3d ago
6K
PPBT
Purple Biotech Shareholders Approve All AGM Proposals, File Results with U.S. SEC
PremiumCompany Announcements
Purple Biotech Shareholders Approve All AGM Proposals, File Results with U.S. SEC
29d ago
6K
PPBT
Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform
PremiumCompany Announcements
Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform
1M ago
6K
PPBT
Purple Biotech issued notice of allowance from USPTO
PremiumThe Fly
Purple Biotech issued notice of allowance from USPTO
1M ago
PPBT
Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform
PremiumCompany Announcements
Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform
2M ago
6K
PPBT
Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright
PremiumThe FlyPurple Biotech price target lowered to $17 from $30 at H.C. Wainwright
2M ago
PPBT
Purple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform
Premium
Company Announcements
Purple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform
2M ago
6K
PPBT
Purple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy
Premium
Company Announcements
Purple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy
2M ago
6K
PPBT
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
PremiumCompany Announcements
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
4M ago
6K
PPBT
Purple Biotech presents new IM1240 data at EACR
PremiumThe Fly
Purple Biotech presents new IM1240 data at EACR
4M ago
PPBT
Purple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform
PremiumCompany Announcements
Purple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform
4M ago
6K
PPBT
Purple Biotech files $200M mixed securities shelf
PremiumThe Fly
Purple Biotech files $200M mixed securities shelf
5M ago
PPBT
Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum
PremiumCompany AnnouncementsPurple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum
5M ago
6K
PPBT
Purple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform
Premium
Company Announcements
Purple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform
5M ago
6K
PPBT
Purple Biotech reports IM1240 demonstrates potent anti-tumor activity
Premium
The Fly
Purple Biotech reports IM1240 demonstrates potent anti-tumor activity
5M ago
PPBT
Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform
PremiumCompany Announcements
Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform
6M ago
6K
PPBT
Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
PremiumCompany Announcements
Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
7M ago
6K
PPBT
Purple Biotech announces collaboration with Converge Bio
PremiumThe Fly
Purple Biotech announces collaboration with Converge Bio
7M ago
PPBT
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
PremiumTipRanks Newswire
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
7M ago
CODX
PPBT
Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
PremiumCompany AnnouncementsPatent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
7M ago
PPBT
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
Premium
Company Announcements
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
7M ago
6K
PPBT
Purple Biotech regains compliance with Nasdaq
Premium
The Fly
Purple Biotech regains compliance with Nasdaq
7M ago
PPBT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >